Use this url to cite publication: https://hdl.handle.net/20.500.12512/94568
Options
Comparison of muscle-derived stem/progenitor cells and bone marrow mesenchymal stem cells for the treatment of acute kidney injury / Eglė Pavydė, Arvydas Ūsas, Romaldas Mačiulaitis
Type of publication
Konferencijų tezės nerecenzuojamame leidinyje / Conference theses in non-peer-reviewed publication (T2)
Title
Comparison of muscle-derived stem/progenitor cells and bone marrow mesenchymal stem cells for the treatment of acute kidney injury / Eglė Pavydė, Arvydas Ūsas, Romaldas Mačiulaitis
Publisher (trusted)
Lithuanian Pharmaceutical Society
Date Issued
2016-04-15
Extent
p. 42-42, no. BFP-16-12.
Is part of
International scientific-practical conference BaltPharm Forum 2016 main theme: Complementary and self-care health products: A pharmacist competences and responsibilities : 15-17 April, 2016, Klaipėda, Lithuania : abstract book / organized by Lietuvos Farmacijos sąjunga in collaboration with EEsti Farmaatsia Selts and Latvijas Farmaceitu Biedriba. Klaipėda : Lithuanian Pharmaceutical Society, 2016. ISBN 9789955956822.
Version
Originalus / Original
Series/Report no.
Summaries of poster presentations.
Description
ISBN 978-9955-9568-2-2.
Field of Science
Abstract
Introduction: The skeletal muscle-derived stem/progenitor cells (MDSPCs) have been thoroughly investigated in preclinical studies. However, the therapeutic potential of MDSPCs for acute kidney injury (AKI) has only been evaluated by our research group. We aimed to compare MDSPCs with bone marrow mesenchymal stem cells (BM-MSCs) and to evaluate their feasibility for the treatment of AKI. Materials and methods: Four groups of rats were used: healthy controls, AKI group, AKI treated with MDSPCs, AKI treated with BM-MSCs. AKI was induced by gentamicin (80 mg/kg/day; i.p.) for 7 consecutive days. PKH-26-labeled MDSPCs and BM-MSCs (1X106 cells/animal) were injected intravenously 24 hours after the last gentamicin injection. Physiological and histological kidney parameters were determined on day 0, 8, 14, 21, 28, 35 (6 animals per time point). Results: Both, MDSPCs and BM-MSCs accelerated functional kidney recovery and regeneration, as reflected by significantly lower serum creatinine levels and renal injury scoring, higher urinary creatinine and GFR levels (p<0.05) compared with the nontreated AKI group. PKH-26 labelled MDSPCs and BM-MSCs were present in the renal cortex on day 9, day 21 and day 35, indicating the capacity of both cell types to migrate and populate the renal tissue. There was no significant difference in any parameters between MDSPCs and BM-MSCs at any time point (p>0.05). Conclusion: Both, MDSPCs and BM-MSCs are capable of mediating functional and histological kidney recovery after AKI. MDSPCs were found equivalent to BM-MSCs, therefore can be considered as a potential candidate for the treatment of AKI.
Type of document
type::text::conference output::conference proceedings::conference paper
ISBN (of the container)
9789955956822
Other Identifier(s)
(LSMU ALMA)990000899090107106
Coverage Spatial
Lietuva / Lithuania (LT)
Language
Anglų / English (en)